Stockscreener 앱 받기
8.00
6.67%
0.50
시간 외 거래:
7.80
-0.20
-2.50%
전일 마감가:
$7.50
열려 있는:
$7.6
하루 거래량:
109.77K
Relative Volume:
1.59
시가총액:
$77.06M
수익:
$1.15M
순이익/손실:
$-46.90M
주가수익비율:
-2.7209
EPS:
-2.9402
순현금흐름:
$865.00K
1주 성능:
+13.48%
1개월 성능:
-9.19%
6개월 성능:
-42.28%
1년 성능:
-6.43%
1일 변동 폭
$7.60
$8.18
1주일 범위
$6.87
$8.29
52주 변동 폭
$6.53
$29.98
Seres Therapeutics Inc Stock (MCRB) Company Profile
명칭
Seres Therapeutics Inc
전화
617 945 9626
주소
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
8.00 | 72.24M | 1.15M | -46.90M | 865.00K | -2.9402 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-08 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-04-21 | 개시 | JP Morgan | Neutral |
| 2021-07-23 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-03-05 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2019-04-30 | 개시 | Jefferies | Hold |
| 2018-10-22 | 개시 | Chardan Capital Markets | Buy |
| 2017-10-13 | 개시 | Oppenheimer | Outperform |
| 2017-08-04 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-01 | 재확인 | FBR & Co. | Outperform |
| 2016-08-12 | 재확인 | FBR Capital | Outperform |
| 2016-08-01 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | 재확인 | H.C. Wainwright | Buy |
| 2016-07-29 | 재개 | H.C. Wainwright | Buy |
| 2016-03-30 | 개시 | FBR Capital | Outperform |
| 2016-03-03 | 개시 | Guggenheim | Buy |
| 2016-01-25 | 개시 | H.C. Wainwright | Buy |
| 2015-10-22 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | 개시 | Canaccord Genuity | Buy |
| 2015-07-21 | 개시 | Goldman | Neutral |
| 2015-07-21 | 개시 | Leerink Partners | Outperform |
모두보기
Seres Therapeutics Inc 주식(MCRB)의 최신 뉴스
CCORF Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Maintains Target Price $22 - Moomoo
MSN Money - MSN
Seres Therapeutics 1Q 2026: Revenue $358K, EPS $(2.08) — 10-Q Summary - TradingView
Seres Therapeutics (NASDAQ: MCRB) Q1 2026 loss and going-concern risk - Stock Titan
Seres Therapeutics: Q1 Earnings Snapshot - marketscreener.com
Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Seres Therapeutics (Nasdaq: MCRB) Q1 2026 results and cash runway - Stock Titan
Seres awaits SER-155 data in weeks with cash through Q3 - Stock Titan
Seres presents preclinical data on IBD drug candidate SER-603 - Investing.com UK
Seres presents preclinical data on IBD drug candidate SER-603 By Investing.com - Investing.com South Africa
Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease - The Manila Times
Experimental IBD microbiome therapy earns DDW poster honor - Stock Titan
Seres Therapeutics Presents Preclinical Data at Digestive - GlobeNewswire
MCRB stock declines as Seres Therapeutics pauses SER-155 phase 2 study and shrinks headcount by 30% - MSN
Seres Therapeutics (MCRB) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Equity plan and director votes in Seres Therapeutics (NASDAQ: MCRB) 2026 proxy - Stock Titan
Microbiome Therapeutics Market is Going to Booming Growth - openPR.com
Chardan Capital Downgrades Seres Therapeutics (MCRB) - MSN
MCRB Price Today: Seres Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below 200 Day Moving AverageHere's What Happened - MarketBeat
Seres Therapeutics (MCRB) Presents Key Data at ESCMID Congress - GuruFocus
Seres Therapeutics (MCRB) Showcases Research at ESCMID 2026 Cong - GuruFocus
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026 - The Manila Times
Seres spotlights microbiome data for transplant patients at ESCMID - Stock Titan
Aug Catalysts: Is Seres Therapeutics Inc impacted by rising rates2026 AllTime Highs & Safe Entry Trade Signal Reports - baoquankhu1.vn
Seres Therapeutics Stock Price Drops Below 50-Day Average - National Today
Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below Fifty Day Moving AverageHere's What Happened - MarketBeat
Will Seres Therapeutics Inc benefit from green energy policies2026 Chart Watch & High Accuracy Trade Alerts - baoquankhu1.vn
Is Seres Therapeutics (MCRB) Stock a Buy Now | Price at $8.51, Down 2.34%Volume Leaders - Newser
Seres Therapeutics to Present at CARB-X Investor Day - Bitget
Seres brings CARB-X-backed ICU infection therapy to Munich event - Stock Titan
Aug Ideas: Should I invest in Seres Therapeutics Inc before earnings2026 Setups & Low Drawdown Trading Strategies - baoquankhu1.vn
VIX Spike: Does Seres Therapeutics Inc have declining or rising EPSWeekly Stock Analysis & Daily Entry Point Alerts - baoquankhu1.vn
MCRB SEC FilingsSeres Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
What are the biggest risks for Seres Therapeutics (MCRB) Stock | Price at $9.27, Up 4.63%Capital Preservation - Cổng thông tin điện tử tỉnh Lào Cai
Market Fear: Can Seres Therapeutics Inc weather a recessionDip Buying & Free High Return Stock Watch Alerts - baoquankhu1.vn
Market Rankings: Is Seres Therapeutics Inc in a bullish channelTrade Volume Summary & Safe Capital Growth Stock Tips - baoquankhu1.vn
Layoff Tracker: Takeda Restructuring Will Affect Workforce, Could Include Layoffs - BioSpace
Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below 50 Day Moving AverageHere's Why - MarketBeat
Seres Therapeutics cuts 25% of workforce to extend cash runway into Q2 2026 - MSN
Seres Therapeutics (MCRB) price target increased by 31.25% to 21.42 - msn.com
If You Invested $1,000 in Seres Therapeutics Inc (MCRB) - Stock Titan
Seres Therapeutics Inc (MCRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.77%
0.25%
자본화:
|
볼륨(24시간):